MedTrace Logo

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-04-03

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Conditions

  • Gastrin-Producing Neuroendocrine Tumor
  • Lung Carcinoid Tumor
  • Metastatic Digestive System Neuroendocrine Tumor G1
  • Multiple Endocrine Neoplasia Type 1
  • Pancreatic Glucagonoma
  • Pancreatic Insulinoma
  • Pancreatic Polypeptide Tumor
  • Recurrent Digestive System Neuroendocrine Tumor G1
  • Recurrent Pancreatic Neuroendocrine Carcinoma
  • Regional Digestive System Neuroendocrine Tumor G1
  • Somatostatin-Producing Neuroendocrine Tumor

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • James Yao · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2014-03-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454363 on ClinicalTrials.gov